A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin

Diabetes Research and Clinical Practice

Volumn 54, Issue 3, 2001, Pages 209-212

  Tokuyama, Y ^a   Nozaki, O ^a   Kanatsuka, A ^a  

^a Kasori Hospital   (Japan)

Author keywords

Heparin; Insulin lispro; Subcutaneous insulin resistance

Indexed keywords

HEPARIN; INSULIN; INSULIN LISPRO; NOVO HEPARIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOINSULINEMIA; INSULIN BLOOD LEVEL; METABOLIC REGULATION; PATHOPHYSIOLOGY; SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HEPARIN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE;

EID: 0034748313     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(01)00314-X     Document Type: Article

References (10)

1. Insulin resistance caused by massive degradation of subcutaneous insulin
2. In search of the subcutaneous-insulin-resistance syndrome
3. Severe insulin resistance treated with insulin lispro
4. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes
5. Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis
6. Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes
7. The biology of vascular endothelial growth factor
8. Structural features in heparin that interact with VEGF165 and modulate its biological activity
9. Heparins in diabetic microangiopathy: Rationale and preliminary clinical results
10. Pathogenesis of diabetic vascular disease: Evidence for the role of reduced heparan sulfate proteoglycan